JP2017511372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511372A5 JP2017511372A5 JP2016562965A JP2016562965A JP2017511372A5 JP 2017511372 A5 JP2017511372 A5 JP 2017511372A5 JP 2016562965 A JP2016562965 A JP 2016562965A JP 2016562965 A JP2016562965 A JP 2016562965A JP 2017511372 A5 JP2017511372 A5 JP 2017511372A5
- Authority
- JP
- Japan
- Prior art keywords
- period
- addnj
- given
- day
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 230000007306 turnover Effects 0.000 claims description 11
- GBRAQQUMMCVTAV-LXGUWJNJSA-N n-[(3s,4r,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)piperidin-3-yl]acetamide Chemical compound CC(=O)N[C@H]1CN[C@H](CO)[C@@H](O)[C@@H]1O GBRAQQUMMCVTAV-LXGUWJNJSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 15
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 9
- BTEHIRWQUADKFP-DUVQVXGLSA-N (4r,5r,6r)-6-(hydroxymethyl)piperidine-2,4,5-triol Chemical compound OC[C@H]1NC(O)C[C@@H](O)[C@@H]1O BTEHIRWQUADKFP-DUVQVXGLSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979408P | 2014-04-14 | 2014-04-14 | |
| US61/979,408 | 2014-04-14 | ||
| US14/684,967 US9675627B2 (en) | 2014-04-14 | 2015-04-13 | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| US14/684,967 | 2015-04-13 | ||
| PCT/US2015/025733 WO2015160796A1 (en) | 2014-04-14 | 2015-04-14 | Dosing regimens for treating and/or preventing cerebral amyloidoses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511372A JP2017511372A (ja) | 2017-04-20 |
| JP2017511372A5 true JP2017511372A5 (https=) | 2019-05-09 |
| JP6662789B2 JP6662789B2 (ja) | 2020-03-11 |
Family
ID=53015935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562965A Expired - Fee Related JP6662789B2 (ja) | 2014-04-14 | 2015-04-14 | 脳アミロイドーシスを処置及び／又は予防する投与計画 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9675627B2 (https=) |
| EP (1) | EP3131547A1 (https=) |
| JP (1) | JP6662789B2 (https=) |
| KR (1) | KR20170003576A (https=) |
| CN (1) | CN107148270A (https=) |
| AU (1) | AU2015247859B2 (https=) |
| CA (1) | CA2945707A1 (https=) |
| HK (1) | HK1243643A1 (https=) |
| SG (1) | SG11201610349SA (https=) |
| WO (1) | WO2015160796A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044437B2 (en) * | 2009-10-19 | 2015-06-02 | Amicus Therapeutics, Inc. | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| US9994589B2 (en) | 2015-12-14 | 2018-06-12 | Amicus Therapeutics, Inc. | Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| ATE156344T1 (de) | 1991-04-25 | 1997-08-15 | Univ Brown Res Found | Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| EP0679088B1 (en) | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP1633356A1 (en) | 2003-05-22 | 2006-03-15 | The Hospital for Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| PL2533050T6 (pl) * | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| WO2007150064A2 (en) | 2006-06-23 | 2007-12-27 | Amicus Therapeutics, Inc. | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| WO2011011181A1 (en) | 2009-07-01 | 2011-01-27 | Amicus Therapeutics, Inc. | Pharmacological chaperones for the treatment of alzheimer's disease |
| US9044437B2 (en) * | 2009-10-19 | 2015-06-02 | Amicus Therapeutics, Inc. | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| SG10201604757RA (en) * | 2011-03-11 | 2016-08-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| KR102076585B1 (ko) * | 2011-12-22 | 2020-02-12 | 센토제너 아이피 게엠베하 | 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물 |
| SMT202100136T1 (it) * | 2012-05-03 | 2021-05-07 | Amicus Therapeutics Inc | Regimi posologici per il trattamento della malattia di pompe |
-
2015
- 2015-04-13 US US14/684,967 patent/US9675627B2/en active Active
- 2015-04-14 AU AU2015247859A patent/AU2015247859B2/en not_active Ceased
- 2015-04-14 HK HK18103256.3A patent/HK1243643A1/zh unknown
- 2015-04-14 KR KR1020167031756A patent/KR20170003576A/ko not_active Withdrawn
- 2015-04-14 CN CN201580031471.1A patent/CN107148270A/zh active Pending
- 2015-04-14 WO PCT/US2015/025733 patent/WO2015160796A1/en not_active Ceased
- 2015-04-14 JP JP2016562965A patent/JP6662789B2/ja not_active Expired - Fee Related
- 2015-04-14 CA CA2945707A patent/CA2945707A1/en not_active Abandoned
- 2015-04-14 SG SG11201610349SA patent/SG11201610349SA/en unknown
- 2015-04-14 EP EP15719362.4A patent/EP3131547A1/en not_active Withdrawn
-
2017
- 2017-06-12 US US15/619,785 patent/US20170273996A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| JP2017075173A5 (https=) | ||
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| Scammell et al. | Coexistence of narcolepsy and Alzheimer's disease | |
| JP2015505564A5 (https=) | ||
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| JP2025137763A (ja) | 絶食条件下でのタシメルテオンの投与 | |
| JP2017506624A5 (https=) | ||
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| JP2013231087A5 (https=) | ||
| Sabbagh et al. | Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response | |
| JP2017501848A5 (https=) | ||
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| JP2016510343A5 (https=) | ||
| JP2019530706A5 (https=) | ||
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2017533220A5 (https=) | ||
| JP2014507475A5 (https=) | ||
| JP2017511372A5 (https=) | ||
| Abuduli et al. | Role of traditional and complementary medicine in universal coverage | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| JP2016505561A5 (https=) |